T-DXd Plus Pertuzumab Sustains PFS Benefit Across HER2+ BC SubgroupsByAriana PelosciOctober 21st 2025
Sacituzumab Govitecan/Pembro Maintains QOL, Physical Functioning in mTNBCByKristie L. KahlOctober 21st 2025
Patient Satisfaction, Comfort Level, and Operational Benefits of SubQ Immune Checkpoint InhibitorsOctober 21st 2025